Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline
About this episode
The episode discusses hepatitis delta virus (HDV) diagnosis, recent FDA approval of bulevirtide, and the challenges in testing implementation.
In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV). Topics covered: Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change The diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation The recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question 10 mg vs. 2 mg dose considerations and off-treatment response data Phase 3 pipeline For more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline
More episodes of HCPLive Podcasts
- 2: Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More
- 1: Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
- Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026
- Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
- Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026
Explore listener stats, chart rankings, contacts and more on the HCPLive Podcasts podcast page.